Seek Returns logo

KDP vs. LLY: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at KDP and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolKDPLLY
Company NameKeurig Dr Pepper Inc.Eli Lilly and Company
CountryUnited StatesUnited States
GICS SectorConsumer StaplesHealth Care
GICS IndustryBeveragesPharmaceuticals
Market Capitalization47.79 billion USD632.40 billion USD
ExchangeNasdaqGSNYSE
Listing DateMay 7, 2008June 1, 1972
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of KDP and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

KDP vs. LLY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolKDPLLY
5-Day Price Return1.59%3.07%
13-Week Price Return3.99%-6.58%
26-Week Price Return10.39%-19.09%
52-Week Price Return-1.24%-23.47%
Month-to-Date Return7.75%-4.68%
Year-to-Date Return9.53%-8.62%
10-Day Avg. Volume7.15M9.65M
3-Month Avg. Volume11.05M4.51M
3-Month Volatility17.08%40.54%
Beta0.470.46

Profitability

Return on Equity (TTM)

KDP

6.23%

Beverages Industry

Max
49.46%
Q3
24.91%
Median
11.13%
Q1
5.27%
Min
-5.93%

KDP’s Return on Equity of 6.23% is on par with the norm for the Beverages industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

KDP vs. LLY: A comparison of their Return on Equity (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

KDP

9.75%

Beverages Industry

Max
21.86%
Q3
12.24%
Median
8.70%
Q1
5.33%
Min
-4.40%

KDP’s Net Profit Margin of 9.75% is aligned with the median group of its peers in the Beverages industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY

25.91%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

KDP vs. LLY: A comparison of their Net Profit Margin (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

KDP

16.89%

Beverages Industry

Max
29.32%
Q3
18.25%
Median
13.42%
Q1
10.58%
Min
0.71%

KDP’s Operating Profit Margin of 16.89% is around the midpoint for the Beverages industry, indicating that its efficiency in managing core business operations is typical for the sector.

LLY

32.37%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

KDP vs. LLY: A comparison of their Operating Profit Margin (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolKDPLLY
Return on Equity (TTM)6.23%88.36%
Return on Assets (TTM)2.87%16.02%
Net Profit Margin (TTM)9.75%25.91%
Operating Profit Margin (TTM)16.89%32.37%
Gross Profit Margin (TTM)54.93%82.64%

Financial Strength

Current Ratio (MRQ)

KDP

0.64

Beverages Industry

Max
3.38
Q3
1.97
Median
1.21
Q1
0.86
Min
0.53

KDP’s Current Ratio of 0.64 falls into the lower quartile for the Beverages industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

LLY

1.28

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

KDP vs. LLY: A comparison of their Current Ratio (MRQ) against their respective Beverages and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

KDP

0.67

Beverages Industry

Max
2.11
Q3
1.23
Median
0.79
Q1
0.32
Min
0.00

KDP’s Debt-to-Equity Ratio of 0.67 is typical for the Beverages industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

LLY

2.18

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

KDP vs. LLY: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Beverages and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

KDP

3.60

Beverages Industry

Max
78.96
Q3
40.67
Median
9.62
Q1
3.59
Min
0.81

KDP’s Interest Coverage Ratio of 3.60 is positioned comfortably within the norm for the Beverages industry, indicating a standard and healthy capacity to cover its interest payments.

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

KDP vs. LLY: A comparison of their Interest Coverage Ratio (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolKDPLLY
Current Ratio (MRQ)0.641.28
Quick Ratio (MRQ)0.330.53
Debt-to-Equity Ratio (MRQ)0.672.18
Interest Coverage Ratio (TTM)3.6020.36

Growth

Revenue Growth

KDP vs. LLY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

KDP vs. LLY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

KDP

2.56%

Beverages Industry

Max
6.93%
Q3
4.51%
Median
3.09%
Q1
2.03%
Min
0.00%

KDP’s Dividend Yield of 2.56% is consistent with its peers in the Beverages industry, providing a dividend return that is standard for its sector.

LLY

0.77%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

KDP vs. LLY: A comparison of their Dividend Yield (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

KDP

54.58%

Beverages Industry

Max
143.36%
Q3
99.22%
Median
67.03%
Q1
40.31%
Min
0.00%

KDP’s Dividend Payout Ratio of 54.58% is within the typical range for the Beverages industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

LLY

36.46%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

KDP vs. LLY: A comparison of their Dividend Payout Ratio (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolKDPLLY
Dividend Yield (TTM)2.56%0.77%
Dividend Payout Ratio (TTM)54.58%36.46%

Valuation

Price-to-Earnings Ratio (TTM)

KDP

31.21

Beverages Industry

Max
41.48
Q3
28.35
Median
19.09
Q1
15.36
Min
3.14

A P/E Ratio of 31.21 places KDP in the upper quartile for the Beverages industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

LLY

47.48

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

KDP vs. LLY: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

KDP

3.04

Beverages Industry

Max
3.90
Q3
2.38
Median
1.54
Q1
0.84
Min
0.41

KDP’s P/S Ratio of 3.04 is in the upper echelon for the Beverages industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

LLY

12.30

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

KDP vs. LLY: A comparison of their Price-to-Sales Ratio (TTM) against their respective Beverages and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

KDP

1.80

Beverages Industry

Max
6.29
Q3
3.58
Median
2.19
Q1
1.68
Min
0.91

KDP’s P/B Ratio of 1.80 is within the conventional range for the Beverages industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

KDP vs. LLY: A comparison of their Price-to-Book Ratio (MRQ) against their respective Beverages and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolKDPLLY
Price-to-Earnings Ratio (TTM)31.2147.48
Price-to-Sales Ratio (TTM)3.0412.30
Price-to-Book Ratio (MRQ)1.8040.43
Price-to-Free Cash Flow Ratio (TTM)30.44326.03